Data from the EVOLVE trial shows the Synergy everolimus-eluting Coronary Stent system, from Boston Scientific, demonstrated non-inferior results in treating...
Synergy Pharmaceuticals, Inc.has announced that plecanatide, its investigational oral drug for the treatment of Chronic Idiopathic Constipation (CIC), was well...
Boston Scientific Corporation has completed enrolment in the EVOLVE II randomized, controlled clinical trial. The EVOLVE II trial is designed...
Maquet Cardiovascular has received the CE mark for its Intergard Synergy vascular graft. This graft combines the antimicrobial properties of...
Synergy Pharmaceuticals Inc. has announced the company has filed with the FDA its first new drug application (NDA) for plecanatide...
Boston Scientific has received FDA approval for the Synergy Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary...
Bausch Health Companies Inc. announced that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals...
Synergy Pharmaceuticals Inc. presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by the FDA...
Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent...
Synergy Pharmaceuticals Inc. announced positive top-line results from the first of two pivotal phase III clinical trials evaluating the efficacy...